Statinum
Statina, inhibitores quoque HMG-CoA reductasis notae, sunt grex lipoproteina minuentia, ideo hyperlipidaemiarum tractationis idonee, medicamentorum.
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt. |
Varia statina adhibentur, ut Atorvastatinum, Lovastatinum, Pravastatinum, Simvastatinum.
Machinatio statinorum
recensereStatina enzymum hydroxy-methylo-glutarylo-coenzymi-A reductasis (HMG-CoA reductasis) inhibitores competitivi obsident. Eo modo statina cholesteroli synthesem inhibent, multitudo LDL in sanguine minuent. Non pronuper investigatores effectus adversarios ad metabolismum spectare quoque monebant, imprimis ad myopathiam statinis[1].
HMG-CoA reductasis
recensere3-Hydroxy-3-methylo-glutarylo-coenzymi A reductasis est a NADH et NADPH dependens enzymum intra iter metabolicum acidi mevalonati, cuius duo producta sunt isopentenyli pyrophosphatum (IPP) et dimethyloallyli pyrophosphatum (DMAPP). Ambo formationis terpenoidorum (seu isoprenoidorum) necesse sunt, propterea terpenoida nidamentum plus quam 30,000 substantiarum chemicarum servant, non solum cholesteroli sed aliarum ut haemis, vitamini K, coenzymi Q10 et omnium hormontum steroidalium[2].
Effectus non grati
recensereMyopathia statinis sociata
recensereInterdum hebdomadibus vel mensibus paucis, quo statinum consumebatur, imbecillitas musculorum observatur. Imbecillitas haec, myopathia dicta, motus corporis impedire queat, etiam renum functionem, si rhabdomyolysis (dissolutio structurarum musculorum) saeviat. Symptomata gravissima vel discontinuationem medicamenti pernecesse faciendi iubeat[3].
Substantiae
recensereStatinum | Metabolimus | Semivita (h) |
---|---|---|
Atorvastatinum | CYP3A4 | 14—19 |
Fluvastatinum | CYP2C9 | 1—3 |
Lovastatinum | CYP3A4 | 1—3 |
Pravastatinum | non CYP | 1—3 |
Rosuvastatinum | CYP2C9, CYP2C19 |
14—19 |
Simvastatinum | CYP3A4 | 1—3 |
Nexus interni
Notae
recensere- ↑ Ahmadi Y, Ghorbanihaghjo A, Naghi-Zadeh M, Yagin NL (2018). "Oxidative stress as a possible mechanism of statin-induced myopathy". Inflammopharmacology
- ↑ Holstein SA, Hohl RJ (2004). "Isoprenoids: remarkable diversity of form and function". Lipids 39 (4): 293-309
- ↑ Tomaszewski M., Stępień K.M., et al. (2011). "Statin-induced myopathies". Pharmaclogical reports 63 (4): 859-66